AC
MDGL icon

Armistice Capital’s Madrigal Pharmaceuticals MDGL Stock Holding History

Armistice Capital’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-320,000
Closed -$73.9M – 267
2023
Q2 		$73.9M Buy
+320,000
New +$86.7M 1.07% 14

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Armistice Capital's MDGL Position: Q2 2026 in Review

Armistice Capital increased its Madrigal Pharmaceuticals (MDGL) stake by 8.9% in Q2 2026, buying an estimated $12M and bringing the position to 288,000 shares worth $155M. The position accounts for 1.89% of the portfolio, ranked #3.

Armistice Capital first reported a position in MDGL in Q1 2015 and has held it in 41 quarters since. The position peaked at $155M in Q4 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Armistice Capital held 288,000 shares of Madrigal Pharmaceuticals worth $155M as of Q2 2026.
  • Armistice Capital bought 23,417 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $12M.
  • Madrigal Pharmaceuticals made up 1.89% of Armistice Capital's portfolio in Q2 2026, its #3 holding.
  • Armistice Capital first reported a position in Madrigal Pharmaceuticals in Q1 2015 and has held it in 41 quarters since.
  • Armistice Capital's Madrigal Pharmaceuticals position peaked at $155M in Q4 2025.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.